Lonsurf and Neupogen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lonsurf (tipiracil hydrochloride; trifluridine) and Neupogen (filgrastim). Common drug interactions include death among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Lonsurf and Neupogen. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Lonsurf?

Lonsurf has active ingredients of tipiracil hydrochloride; trifluridine. eHealthMe is studying from 10,077 Lonsurf users. Check the latest studies of Lonsurf.

What is Neupogen?

Neupogen has active ingredients of filgrastim. It is often used in agranulocytosis. eHealthMe is studying from 23,898 Neupogen users. Check the latest studies of Neupogen.



On Aug, 05, 2026

19 people who take Lonsurf and Neupogen together, and have interactions are studied.

Lonsurf and Neupogen drug interactions.

What are the common drug interactions of Lonsurf and Neupogen, by gender? *:

female:

  1. Death
  2. Disease progression
  3. Diarrhoea
  4. Dysgeusia (disorder of the sense of taste)
  5. Fatigue (feeling of tiredness)
  6. Nausea (feeling of having an urge to vomit)
  7. Abdominal pain
  8. Abdominal pain upper
  9. Alopecia (absence of hair from areas of the body)
  10. Decreased appetite

male:

  1. Fatigue (feeling of tiredness)
  2. Nausea (feeling of having an urge to vomit)
  3. Anaemia (lack of blood)
  4. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  5. Red blood cell count decreased
  6. Thrombocytopenia (decrease of platelets in blood)
  7. Urinary tract infection
  8. White blood cell count decreased
  9. Abdominal pain
  10. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

What are the common drug interactions of Lonsurf and Neupogen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Disease progression
  2. Fatigue (feeling of tiredness)
  3. Nausea (feeling of having an urge to vomit)
  4. Vomiting

40-49:

  1. Fatigue (feeling of tiredness)
  2. Nausea (feeling of having an urge to vomit)
  3. Death

50-59:

  1. Death
  2. Disease progression
  3. Anaemia (lack of blood)
  4. Bone pain
  5. Chest pain
  6. Diarrhoea
  7. Dysgeusia (disorder of the sense of taste)
  8. Dyspnoea exertional (breathlessness or shortness of breath)
  9. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  10. Leukopenia (less number of white blood cells in blood)

60+:

  1. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  2. Abdominal pain
  3. Abdominal discomfort
  4. Anaemia (lack of blood)
  5. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  6. Death
  7. Dehydration (dryness resulting from the removal of water)
  8. Disease progression
  9. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  10. Myalgia (muscle pain)

What are the existing conditions these people have? *

  1. Colon Cancer: 9 people, 47.37%
  2. Rectal Cancer (cancer of rectum): 3 people, 15.79%
  3. Metastases To Liver (cancer spreads to liver): 3 people, 15.79%
  4. Rectosigmoid Cancer (cancer that originates in the rectum and sigmoid colon): 2 people, 10.53%
  5. Metastases To Biliary Tract (cancer spreads to biliary tract): 2 people, 10.53%
  6. Colon Cancer Metastatic (cancer of colon spreads to other part of body): 2 people, 10.53%
  7. Pain: 1 person, 5.26%
  8. Oesophageal Carcinoma (cancer tumour of oesophagus): 1 person, 5.26%
  9. Metastases To Lung (cancer spreads to lung): 1 person, 5.26%
  10. Metastases To Bone (cancer spreads to bone): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Lonsurf and Neupogen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lonsurf and Neupogen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lonsurf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Neupogen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lonsurf and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neupogen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tipiracil hydrochloride; trifluridine and filgrastim (the active ingredients of Lonsurf and Neupogen, respectively), and Lonsurf and Neupogen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: